16 September 2000

Contents

Treatment alerts

• Abacavir hypersensitivity cases following an interruption of therapy

Antiretrovirals

• Videx EC (ddI, didanosine) – food restrictions

• Importance of protease inhibitor plasma levels in patients treated with genotypic-guided therapy

• Flavopiridol inhibits cellular processes essential to replication of HIV

• Abbott expands early-access program for ABT-378/r (Kaletra)

• Roche and Trimeris announce intention to manufacture commercial supplies of anti-HIV fusion inhibitor T-20

• PRO-542 shows efficacy in trial

Treatment strategies

• Structured treatment interruptions and treatment intensification

Treatment access

• Loans to buy AIDS drugs are rejected by Africans

Paediatric care

• Adverse effects of perinatal zidovudine exposure on HIV-infected infants

• Early cognitive and motor developmental delays in HIV-infected infants

• Topical cidofovir clears severe molluscum contagiosum in children with AIDS

Side effects

• HAART: enough to make your hair curl?

Coinfections and complications

• Prevalence of psoriatic arthritis increasing among HIV-positive black Zambians

Basic science and immunology

• Duration of incubation affects subsequent rate of HIV disease progression

• Population of HIV-targeted CD8 cells fluctuates with viral load during chronic infection

Vaccines and microbicides

• Murabutide inhibits HIV replication in macrophages and dendritic cells

Other news

• Scrub typhus: infection reduces viral load in some patients

• Immunorestitution disease